Suriname’s Minister of Public Health, Welfare and Labor (VWA), André Misiekaba, has announced the government’s ongoing push for systemic, long-term improvements to the country’s medication supply network, with the goal of making essential drugs more accessible and affordable for all citizens in the near term. In a recent statement outlining the government’s policy priorities, Misiekaba framed essential medication as a core strategic public good that requires active state stewardship, rather than being left to unregulated market forces. He drew a direct parallel between reliable medication access and other fundamental public infrastructure such as potable water and electrical power, noting that the state bears a central responsibility for maintaining all three critical services. “For me, medication is a strategic asset, just like drinking water and electricity,” Misiekaba stated. “Just as we never cede control over these basic provisions, essential medicines must remain within the state’s sphere of responsibility.”
At the heart of the country’s medication supply system is the Suriname Pharmaceutical Supply Company (BGVS), a state-owned entity established in 1983 tasked with the centralized procurement and distribution of essential generic medications, commonly referred to as “klappermedicamenten” in Suriname. Misiekaba explained that when the current administration took office, a review found that the BGVS had been significantly weakened over preceding years, eroding its role as the nation’s key drug price regulator and primary supplier. This institutional decline, he noted, directly translated into widespread shortages and inflated prices for life-saving medications across Suriname, leaving many residents unable to access the treatments they need.
To reverse these declines, the government has implemented a series of targeted recovery measures over the past several months. These changes include the appointment of a new executive leadership team at BGVS, the partial clearance of the organization’s outstanding debt, and ongoing government investment to strengthen both the financial position and operational capacity of the state drug agency. Additional public funds have also been allocated to allow BGVS to negotiate directly with international pharmaceutical suppliers and secure bulk purchases of essential medications at lower cost.
Looking ahead, Misiekaba expressed confidence that Suriname’s population will begin to see tangible improvements in essential medication availability over the coming months. He reaffirmed the government’s long-term commitment to building a sustainable, inclusive public health system that guarantees all Surinamese citizens equal access to necessary life-saving medications.